anti-cancer - Available Technologies | Rutgers University Innovation Ventures

Search Results - anti-cancer

26 Results Sort By:
CAR-NK based combinatorial treatment for drug-resistant tumors
​ ​ Incucyte Killing Assay Images with AnnexinV cell death signal in MKI-Resistant HCC (Top panel). Chromium-51 release assays comparing GRP78 CAR-NK Killing to Naïve NK killing of various MKI-resistant tumor cell lines (bottom panels). Values shown are Means ± SEM. Significant p values indicated in red. Invention Summary: CAR-NK...
Published: 5/8/2024   |   Inventor(s): Dongfang Liu, Youssef Sabha, Chih-Hsiung Chen
Keywords(s): Anti-cancer
Category(s): Technology Classifications > Cell Therapy, Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
A novel inhibitory mimetic peptide slows down tumor development
​ ​ Inhibitory peptide increases caspase3 activity (A) by blocking GC1/Trx1 complex thereby limiting cell proliferation by inducing cell death (B). Invention Summary: Soluble guanylyl cyclase (GC1) and thioredoxin 1 (Trx1), when physically interacting and attaching to each other, they acquire the ability to induce changes in other target...
Published: 4/25/2024   |   Inventor(s): Annie Beuve
Keywords(s): Anti-cancer
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Cancer
Off-the-Shelf CAR-Macrophages for Solid Tumors
​ ​ Invention Summary: Chimeric Antigen Receptor (CAR) therapy requires isolation of the respective immune cells from the patient’s blood, genetic manipulation, and infusion of the modified cells back into the patient’s body. This makes it personalized and effective but expensive. The CAR-T (modified T cells) therapy has shown...
Published: 1/11/2024   |   Inventor(s): Pingping Hou
Keywords(s): Anti-cancer
Category(s): Technology Classifications > Cell Therapy, Technology Classifications > Cancer, Technology Classifications > Healthcare & Life Sciences
DEVELOPMENT OF SPECIFIC CRK-LIKE ADAPTOR PROTEIN INHIBITORS FOR CANCER THERAPY
NC5 inhibits tumor growth and prolongs survival in vivo. NC5 treatment inhibits TNBC tumor growth and prolongs mice survival in xenograft and PDX mouse models. (A) Survival of mice bearing MDA-MB-231-Luc orthotopic xenograft tumors following treatment with vehicle (black line), Gleevec (blue line), or NC5 (red line). (B) Survival of mice bearing PDX...
Published: 4/21/2024   |   Inventor(s): Dongfang Liu, Xuening Wang
Keywords(s): Anti-cancer, Proteins
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Cancer
Method for Generating Memory T-cells In Vitro and Their Use in Immunotherapy
Invention Summary: Dendritic cell-based immunotherapies have been tested for the treatment of cancer patients with limited success. The limited success is probably due to the ineffective activation of specific T-cells by injected dendritic cells. In vitro generation of memory T-cells that can respond to cancer cells could circumvent ineffective T-cell...
Published: 11/3/2022   |   Inventor(s): Shigeko Yamashiro (Matsumura), Fumio Matsumura, Aya Matsumura
Keywords(s): Anti-cancer, Immunoassay
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Research Tools, Technology Classifications > Therapeutics
SAHMI: Microbiome-based screening method for cancer and other diseases
​ ​ Screening methodology and principle data identifying differences in microbiome diversity from disease state in pancreatic cancer Invention Summary: The microbiome plays an essential role in the prognosis and progression of disease and health, as seen in cancers like pancreatic cancer. Pancreatic cancer is rising in majority of cancer...
Published: 8/8/2022   |   Inventor(s): Subhajyoti De, Bassel Ghaddar
Keywords(s): Anti-cancer, Bioinformatics, Biomarkers, Cancer biomarkers
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Diagnostics, Technology Classifications > Cancer
Combined Opioidergic and Beta-Adrenergic Drugs for Cancer and Immune Diseases
­​ Figure 1. (Left) Combined, synergistic treatment with naltrexone (NTX), propranolol (PRO), and Anti-PD1 antibody shows decrease in tumor size, by volume. (Right) Combined treatment of NTX, DPDPE, and PRO similarly decreases tumor size compared to controls. Invention Summary: One of the major cancer therapy approaches that is being...
Published: 5/8/2024   |   Inventor(s): Dipak Sarkar
Keywords(s): Anti-cancer, Small molecules
Category(s): Technology Classifications > Cancer, Technology Classifications > Healthcare & Life Sciences
Iodinated Salicylate-Polymers
​ ​ FIG. 2( a) is a cross-sectional view of an apparatus or article including a medical device and an iodinated polymer coating in accordance with some embodiments. FIG. 2( b) is a perspective view of the medical device, shown in FIG. 2( a), having a surface that is partially coated with the iodinated polymer coating in accordance...
Published: 4/17/2024   |   Inventor(s): Kathryn Uhrich, Ashley Carbone
Keywords(s): Anti-cancer, Drug Delivery, Imaging, Implants, Polymers & Composites, Wound healing
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics, Technology Classifications > Polymers/Composites/Materials
Biomarkers for Identifying Patients at High Risk of Progressing from Barrett’s Esophagus to Esophageal Adenocarcinoma
Invention Summary: Esophageal adenocarcinoma (EAC) has a poor prognosis with a 5-year overall survival of 15-20%. In the past 3 decades, the incidence of EAC increased 600-800%. Barrett’s esophagus (BE), the precancerous lesion for EAC, has approximately 0.11 to 1.6% annual rate of progression to EAC. Currently, the guidelines for BE surveillance...
Published: 5/8/2024   |   Inventor(s): Zhongren ("David") Zhou
Keywords(s): Anti-cancer, Biomarkers, Cancer biomarkers
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Diagnostics, Technology Classifications > Cancer
Leukemia inhibitory factor- Protective role for radiation/chemo-induced gut syndrome and GVHD
Invention Summary: Currently there is no effective therapy for prevention or treatment of radiation therapy-induced gastrointestinal (GI) tract injury This is also true for Graft-versus-host disease (GVHD) which remains a major complication after allogeneic hematopoietic stem cell transplantation, a widely-used therapy for hematologic malignancies...
Published: 10/4/2022   |   Inventor(s): Wenwei Hu, Zhaohui Feng, Jianming Wang, Huaying Wang
Keywords(s): Anti-cancer, Gastrointestinal disease, Peptides
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Cancer, Technology Classifications > Therapeutics
1 2 3